Susan Pandya joined Atavistik Bio as Chief Medical Officer in September 2025. Susan is an oncologist and drug developer with nearly 20 years of experience advancing breakthrough cancer therapies. At Atavistik Bio, she leads clinical development strategy and execution, driving programs from early development into efficient, high-impact clinical trials, including the company’s lead program, ATV-1601.
Susan previously served as Vice President of Clinical Development and Global Head of Late-Stage Oncology at Servier Pharmaceuticals, where she led global oncology and hematology programs and played an integral role in portfolio and business development strategy. Before Servier, she led development of the IDH inhibitor portfolio at Agios Pharmaceuticals, including TIBSOVO® and VORANIGO®, overseeing pivotal Phase 3 trials and multiple global approvals across indications such as AML, MDS, cholangiocarcinoma, and glioma.
Earlier in her career, Susan worked in early-phase development at Acceleron Pharma. She earned her MD from Tufts University School of Medicine and completed her residency in internal medicine and fellowship hematology/oncology at Beth Israel Deaconess Medical Center, where she also maintained a clinical practice. She currently serves on the Board of Directors of MOMA Therapeutics.